Table 3.
Risk of NAFLD progression according to the RASi exposures.
| NAFLD progression | Non-NAFLD progression | Conditional logistic regression | ||||||
|---|---|---|---|---|---|---|---|---|
| Total | Men | Women | ||||||
| Total (men, women) | Total (men, women) | aORa (95% CI) | p | aORa (95% CI) | p | aORa (95% CI) | p | |
| RASi use | ||||||||
| Never | 2001 (1334, 667) | 2008 (1386, 622) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | |||
| Ever | 521 (307, 214) | 514 (297, 217) | 0.94 (0.80–1.11) | 0.465 | 1.02 (0.82–1.26) | 0.884 | 0.88 (0.66–1.18) | 0.395 |
| RASi cumulative daily defined dose (cDDD) | ||||||||
| > 0–90 | 127 (77, 50) | 141 (88, 53) | 0.81 (0.61–1.07) | 0.136 | 0.82 (0.56–1.18) | 0.281 | 0.79 (0.48–1.31) | 0.365 |
| 90–180 | 51 (27, 24) | 42 (23, 19) | 1.14 (0.72–1.79) | 0.576 | 1.28 (0.68–2.39) | 0.444 | 1.16 (0.54–2.51) | 0.705 |
| 180–365 | 59 (35, 24) | 55 (29, 26) | 1.05 (0.69–1.58) | 0.832 | 1.28 (0.73–2.27) | 0.391 | 1.12 (0.57–2.18) | 0.751 |
| 365–720 | 71 (32, 39) | 71 (41, 30) | 0.83 (0.57–1.21) | 0.335 | 0.77 (0.45–1.31) | 0.338 | 1.00 (0.53–1.87) | 0.989 |
| ≥ 720 | 213 (136, 77) | 205 (116, 89) | 1.01 (0.80–1.27) | 0.925 | 1.13 (0.84–1.53) | 0.427 | 0.77 (0.49–1.19) | 0.237 |
| RASi total prescription days | ||||||||
| > 0–180 | 184 (109, 75) | 180 (110, 70) | 0.92 (0.72–1.17) | 0.510 | 0.96 (0.70–1.32) | 0.808 | 0.87 (0.57–1.34) | 0.540 |
| 180–365 | 52 (26, 26) | 63 (40, 23) | 0.84 (0.56–1.27) | 0.404 | 0.72 (0.42–1.26) | 0.255 | 1.65 (0.84–3.27) | 0.148 |
| 365–720 | 73 (40, 33) | 73 (37, 36) | 0.84 (0.58–1.22) | 0.369 | 1.04 (0.61–1.78) | 0.882 | 0.69 (0.37–1.31) | 0.260 |
| ≥ 720 | 212 (132, 80) | 198 (110, 88) | 1.03 (0.82–1.30) | 0.777 | 1.16 (0.86–1.58) | 0.338 | 0.79 (0.51–1.22) | 0.290 |
| RASi mean prescribed daily dose (PDD) | ||||||||
| > 0–0.5 | 4 (3, 1) | 4 (3, 1) | 1.14 (0.26–4.99) | 0.862 | 0.98 (0.16–6.03) | 0.981 | – | – |
| 0.5–1 | 92 (59, 33) | 93 (45, 48) | 0.94 (0.67–1.30) | 0.694 | 1.52 (0.98–2.37) | 0.063 | 0.49 (0.26–0.93) | 0.030 |
| 1–1.5 | 336 (190, 146) | 322 (182, 140) | 0.96 (0.79–1.16) | 0.642 | 0.99 (0.76–1.28) | 0.929 | 0.94 (0.68–1.31) | 0.726 |
| ≥ 1.5 | 89 (55, 34) | 95 (67, 28) | 0.89 (0.64–1.24) | 0.500 | 0.77 (0.51–1.18) | 0.232 | 1.16 (0.63–2.16) | 0.630 |
aAdjusted for age, body mass index, waist circumference, fasting plasma glucose, α-glucosidase inhibitor, β-blocker, metformin, sulfonylurea, thiazolidinedione, Charlson comorbidity index score, diabetes, hypertension.
CI confidence interval, NAFLD non-alcoholic fatty liver disease, OR odds ratio, RASi renin–angiotensin–aldosterone system inhibitor.